Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel for relapse prevention in MDD
NCT03614156Phase 3Terminated
- Sponsor
- Allergan
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (3 arms), sponsored by Allergan. Primary endpoint: Time to First Relapse During the 52 Weeks of the Double-Blind Treatment Period (DBTP). Started Aug 2018; status: terminated.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03614156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614156.